Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages.
Andrieu JM, Jais JP, Colonna P, Desablens B, Brière J, François S, Harousseau JL, Casassus P, Lemevel A, Le Prisé PY, Ghandour C, Guilhot F, Lejeune F. Andrieu JM, et al. Among authors: desablens b. Ann Oncol. 1998 Feb;9(2):195-203. doi: 10.1023/a:1008232228653. Ann Oncol. 1998. PMID: 9553666 Clinical Trial.
Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
Sénécal D, Jais JP, Desablens B, Berthou C, Casassus P, Moles MP, Delwail V, Gastinne T, Colonna P, Andrieu JM. Sénécal D, et al. Among authors: desablens b. Cancer. 2008 Feb 15;112(4):846-55. doi: 10.1002/cncr.23247. Cancer. 2008. PMID: 18072259 Free article.
Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
Djeridane M, Oudard S, Escoffre-Barbe M, Lacotte-Thierry L, Desablens B, Briére J, Dib M, Cassasus P, Ghandour C, Lamy T, Lejeune F, Simon M, Traullé C, Vigier M, Maisonneuve H, Briére J, Colonna P, Andrieu JM. Djeridane M, et al. Among authors: desablens b. Cancer. 2002 Nov 15;95(10):2169-79. doi: 10.1002/cncr.10932. Cancer. 2002. PMID: 12412171 Free article. Clinical Trial.
Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial.
le Maignan C, Desablens B, Delwail V, Dib M, Berthou C, Vigier M, Ghandour C, Atmani S, Casassus P, Maisonneuve H, Le Mevel A, Traulle C, Bernard M, Briere J, Colonna P, Andrieu JM. le Maignan C, et al. Among authors: desablens b. Blood. 2004 Jan 1;103(1):58-66. doi: 10.1182/blood-2003-05-1611. Epub 2003 Aug 7. Blood. 2004. PMID: 12907440 Free article. Clinical Trial.
Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients.
Colonna P, Jais JP, Desablens B, Harousseau JL, Brière J, Boasson M, Lemevel A, Casassus P, Le Prisé PY, Guilhot F, Ghandour C, Lejeune F, Andrieu JM. Colonna P, et al. Among authors: desablens b. J Clin Oncol. 1996 Jun;14(6):1928-35. doi: 10.1200/JCO.1996.14.6.1928. J Clin Oncol. 1996. PMID: 8656262
Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France.
Foussard C, Desablens B, Sensebe L, François S, Milpied N, Deconinck E, Delwail V, Dugay J, Lamy T, Ghandour C, Le Mevel A, Maisonneuve H, Casassus P, Colombat P. Foussard C, et al. Among authors: desablens b. Ann Oncol. 1997;8 Suppl 1:49-52. Ann Oncol. 1997. PMID: 9187429 Clinical Trial.
Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy.
Vigouroux S, Milpied N, Andrieu JM, Colonna P, Ifrah N, Colombat P, Desablens B, Abgrall JF, Casassus P, Guilhot F, Briere J, Le Mevel A, Moreau P, Mechinaud F, Mahe B, Morineau N, Vigier M, Rapp MJ, Harousseau JL. Vigouroux S, et al. Among authors: desablens b. Bone Marrow Transplant. 2002 May;29(10):833-42. doi: 10.1038/sj.bmt.1703547. Bone Marrow Transplant. 2002. PMID: 12058233
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies.
Foussard C, Colombat P, Maisonneuve H, Berthou C, Gressin R, Rousselet MC, Rachieru P, Pignon B, Mahé B, Ghandour C, Desablens B, Casassus P, Lamy T, Delwail V, Deconinck E. Foussard C, et al. Among authors: desablens b. Ann Oncol. 2005 Mar;16(3):466-72. doi: 10.1093/annonc/mdi091. Epub 2005 Feb 2. Ann Oncol. 2005. PMID: 15695500 Free article. Clinical Trial.
121 results